Price (delayed)
$0.46
Market cap
$40.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.1
Enterprise value
$43.76M
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics
There are no recent dividends present for AVCO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.